Breast cancer is the leading nonhematologic cause of meningeal carcinomatosis (MC), a unusual metastatic site. Its treatment generally relies on intrathecally and/or systematically delivered chemotherapy, combined with radiotherapy or surgery when needed. However, the overall survival (OS) of patients with proven MC is short, generally no longer than 6 months after the diagnosis of MC [1] . A retrospective study on 91 breast cancer MC diagnosed and treated homogeneously by a high-dose intrathecal methotrexate regimen [2] at the Institut Curie (Paris, France) from 2000 to 2007 has been recently reported [3] . This study retrieved four adverse independent prognostic factors at MC diagnosis: performance status (PS) of three to four, elevated Cyfra 21-1 marker in the cerebrospinal fluid (CSF), negative hormone receptors (HR) status and more than three previous chemotherapy lines for metastatic disease. Two prognostic scores were derived from these results, based on the number of adverse prognostic factors: the complete score included the four prognostic factors, whereas the simplified score did not include CSF Cyfra 21-1 as its dosage is not made routinely in this setting. Both prognostic scores allowed to classify patients into three groups with poor, intermediate and good prognosis (median OS of 2, 4 and 12 months, respectively). These scores required further validation.
cancer and MC, 9 of them being not included in the analysis (patients treated in another institution or diagnosed with another stage IV cancer). For the remaining 79 patients, PS, HR status and number of previous chemotherapy lines at MC diagnosis were obtained in their electronic medical files, together with their OS from the time of MC diagnosis (66 deaths and 13 censored). First-line intrathecal treatments were as follow: liposomal cytarabine (n = 27 patients), methotrexate (n = 24), thiotepa (n = 1), no intrathecal treatment (n = 15) and unknown (n = 12, insufficiently documented in the supporting medical records). Other treatment modalities were mainly radiotherapy (n = 26) and systemic chemotherapy (n = 16). OS curve is shown in Figure 1A (median 2.6 months). A multivariate analysis confirmed the independent role of each prognostic factor included in the simplified score (Table 1) . This score was calculated individually, each adverse prognostic factor being scored as 1 point, leading to a total score ranging from 0 to 3. OS curves according to the simplified score are shown in Figure 1B (P < 0.0001): median OS were 1.1, 2.0 and 6.5 months, respectively, in the poor (n = 21 patients), intermediate (n = 26 patients) and good (n = 20 patients) prognostic group. Similar results were obtained after excluding the 12 patients with unknown treatment (P < 0.0001). Interestingly, these curves looked very similar to those reported initially [3] , with 25% of 'long-term survivors' (OS > 1 year) in the good prognostic group.
In this retrospective study, the simplified prognostic score has been therefore validated, although treatment modalities were different and did not systematically rely on intrathecally delivered chemotherapy. Although clinically relevant, the simplified score may be not specific to MC as it relies on three prognostic factors validated in the whole metastatic setting. Our study call for further prospective validation of the simplified score and comparison to the complete prognostic score, which may be more specific as it includes tumor marker in the CSF. Further validated score may be used in this heterogeneous population to stratify patients in future therapeutic trials. 
